clinical trials

Yehya A, Lopez J, Sauer AJ, Davis JD, Ibrahim NE, Tung R, Bozkurt B, Fonarow GC, Al-Khatib SM. Revisiting ICD Therapy for Primary Prevention in[...]

By sjmartinez • December 7, 2024

Hughes BGM, Guminski A, Bowyer S, Migden MR, Schmults CD, Khushalani NI, Chang ALS, Grob JJ, Lewis KD, Ansstas G, Day F, Ladwa R, Stein[...]

By sjmartinez • September 9, 2024

Khalid SN, Mansoor T, Bilal MI, Ijaz SH, Fudim M, Greene SJ, Nambi V, Virani SS, Fonarow GC, Abramov D, Minhas AMK. Ongoing and Future[...]

By sjmartinez • August 20, 2024

Peipert JD, Roydhouse J, Tighiouart M, Henry NL, Kim S, Hays RD, Rogatko A, Yothers G, Ganz PA. Overall side effect assessment of oxaliplatin toxicity[...]

By sjmartinez • July 31, 2024

Korman NJ, Warren RB, Bagel J, Armstrong AW, Gooderham M, Strober B, Thaçi D, Morita A, Imafuku S, Foley P, Sofen H, Zheng M, Hippeli[...]

By sjmartinez • July 1, 2024

Budoff MJ. Testosterone Repletement: Is it the TRAVERSE Trial or a Travesty? JACC Adv. 2023 Nov 12;2(10):100742. doi: 10.1016/j.jacadv.2023.100742. PMID: 38938483; PMCID: PMC11198716.

By sjmartinez • June 28, 2024

Marks J, Sridhar A, Ai A, Kiel L, Kaufman R, Abioye O, Mantz C, Florez N. Precision Immuno-Oncology in NSCLC through Gender Equity Lenses. Cancers[...]

By sjmartinez • April 14, 2024

Chen K, Jackson NJ, Kelesidis T. Mitoquinone mesylate as post-exposure prophylaxis against SARS-CoV-2 infection in humans: an exploratory single center pragmatic open label non-randomized pilot[...]

By sjmartinez • March 12, 2024

Hamid A, Fonarow GC, Butler J, Hall ME. How do breast cancer clinical trials approach cardiovascular safety: targeted or generalized? Cardiooncology. 2024 Feb 7;10(1):6. doi:[...]

By sjmartinez • February 7, 2024

Mohtashemi N, Dubé K, Thio C, Song S, Patel S, Sugarman J, Bhattacharya D. Patient acceptability of, and attitudes towards, hepatitis B cure research -[...]

By sjmartinez • January 3, 2024